Oncology Strategic Roundup | July 02 – Aug 07, 2026
Oncology Strategic Roundup exploring Developments and Competitive Shifts…
Johnson & Johnson Firefly Bio Acquisition | Lucid Diligence Brief
Johnson & Johnson's $1 billion Firefly Bio acquisition highlights a…
Massive Bio and GELL Partnership | Lucid Diligence Brief
Massive Bio and GELL have launched a strategic partnership to expand AI-enabled…
Harbour BioMed and Sinopharm Innovation Consortium Expands Biologics Strategy | Lucid Diligence Brief
Harbour BioMed partners with Sinopharm to establish an innovation consortium…
Excalipoint Therapeutics and DP Technology Partnership | Lucid Diligence Brief
Excalipoint Therapeutics and DP Technology have partnered to develop an agentic…
Innovent-Lilly Verzenios China Commercialization | Lucid Diligence Brief
Innovent takes mainland China commercial responsibility for Verzenios as Lilly…
LabGenius and LG Chem Advance Multispecific Antibody Partnership | Lucid Diligence Brief
LabGenius expands validation of its EVA antibody-discovery platform through a…
Lonza Antharis Dual-Payload ADC License | Lucid Diligence Brief
Lonza and Antharis license dual-payload ADC technology for gastrointestinal…
GSK Acquires Nuvalent to Expand Oncology Pipeline | Lucid Diligence Brief
GSK strengthens its oncology portfolio with Nuvalent acquisition, adding…
Nurix Roche Bexobrutideg Deal | Lucid Diligence Brief
Roche’s collaboration with Nurix turns bexobrutideg into a multi-indication BTK…
Public Health Today—June 5, 2026
This weekly update in Public Health highlights major developments across…
Stipple Bio’s Lonza ADC Deal | Lucid Diligence Brief
Stipple Bio’s Lonza ADC license raises the execution test for STP-100 and…